Use of Iptacopan for C3 Glomerulopathy, Interim Analysis of Phase 2 Study

With: Brian Mandell, MD, PhD, MACR, MACP and Ali Mehdi MD, MEd, FACP, FASN

Brian Mandell, MD, PhD, MACR, MACP and Ali Mehdi MD, MEd, FACP, FASN from Cleveland Clinic review the abstract, 12M Interim Analysis of an Open-Label, Non-Randomized Extension of a Phase 2 Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Iptacopan in Subjects With C3G, presented at Kidney Week 2022.

← Back to Kidney Week 2022